Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: A review

PharmacoEconomics

Volumn 29, Issue 3, 2011, Pages 199-211

  Boonacker, Chantal W B ^a   Broos, Pieter H ^a   Sanders, Elisabeth A M ^b   Schilder, Anne G M ^a,b   Rovers, Maroeska M ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; CHILD CARE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HUMAN; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 79951627780     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11584930-000000000-00000     Document Type: Review

References (53)

1. Bondy J, Berman S, Glazner J, et al. Direct expenditures related to otitis media diagnoses: extrapolations from a pediatric medicaid cohort. Pediatrics 2000 Jun; 105 (6): E72
2. Rovers MM, Schilder AG, Zielhuis GA, et al. Otitis media. Lancet 2004 Feb 7; 363 (9407): 465-73 (Pubitemid 38210066)
3. Gates GA. Cost-effectiveness considerations in otitis media treatment. Otolaryngol Head Neck Surg 1996 Apr; 114 (4): 525-30 (Pubitemid 26114246)
4. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000 Mar; 19 (3): 187-95 (Pubitemid 30167436)
5. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006 Mar 4; 367 (9512): 740-8 (Pubitemid 43326292)
6. De Carvalho GH, Muscat M, Monnet DL, et al. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill 2009 Mar 26; 14 (12): 19159
7. O'Brien MA, Prosser LA, Paradise JL, et al. New vaccines against otitismedia: projected benefits and cost-effectiveness. Pediatrics 2009 Jun; 123 (6): 1452-63
8. Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010 Apr; 29 (4): 304-9
9. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001 Feb 8; 344 (6): 403-9 (Pubitemid 32128672)
10. Jansen AG, Hak E, Veenhoven RH, et al. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev 2009 Apr 15; (2): CD001480
11. Pichichero ME, Casey JR. Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era. Pediatr Infect Dis J 2007 Oct; 26 (10 Suppl.): S12-6
12. Organisation for Economic Co-operation and Development (OECD). Price indices (MEI) [online]. Available from URL: http://stats.oecd.org/Index.aspx? DataSetCode=MEI-PRICES [Accessed 2010 Nov 24]
13. Exchange-Rates.org [online]. Available from URL: http://www.exchange- rates.org [Accessed 2010 Apr 6]
14. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996 Aug 3; 313 (7052): 275-83 (Pubitemid 26254740)
15. Asensi F, De Jose M, Lorente M, et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health 2004 Jan; 7 (1): 36-51 (Pubitemid 38186283)
16. Bergman A, Hjelmgren J, Ortqvist A, et al. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden [abstract]. Scand J Infect Dis 2008; 40 (9): 721-9
17. Bos JM, Rumke H, Welte R, et al. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther 2003 Oct; 25 (10): 2614-30 (Pubitemid 37373936)
18. Bos JM, Rumke HC, Welte R, et al. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands. Pharmacoeconomics 2006; 24 (2):141-53 (Pubitemid 43242196)
19. Butler JR, McIntyre P, MacIntyre CR, et al. The costeffectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 2004; 22 (9-10): 1138-49 (Pubitemid 38296656)
20. Claes C, Graf von der Schulenburg JM. Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Pharmacoeconomics 2003; 21 (8): 587-600 (Pubitemid 36688102)
21. Ess SM, Schaad UB, Gervaix A, et al. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine 2003; 21 (23): 3273-81 (Pubitemid 36694568)
22. Giglio ND, Cane AD, Micone P, et al. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine 2010; 28 (11): 2302-10
23. Lebel MH, Kellner JD, Ford-Jones EL, et al. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin Infect Dis 2003; 36 (3): 259-68 (Pubitemid 36169659)
24. LieuTA,RayGT, Black SR, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000; 283 (11): 1460-8 (Pubitemid 30151825)
25. Lloyd A, Patel N, Scott DA, et al. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ 2008; 9 (1): 7-15
26. McIntosh ED, Conway P, Willingham J, et al. The costburden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine 2003; 21 (19-20): 2564-72 (Pubitemid 36561349)
27. Navas E, Salleras L, Gisbert R, et al. Cost-benefit and costeffectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine 2005 Mar 18; 23 (17-18): 2342-8
28. Ray GT, Pelton SI, Klugman KP, et al. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine 2009 Nov 5; 27 (47): 6483-94
29. Salo H, Sintonen H, Nuorti JP, et al. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand J Infect Dis 2005; 37 (11-12): 821-32
30. Silfverdal SA, Berg S, Hemlin C, et al. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine. Vaccine 2009; 27 (10): 1601-8
31. Sohn HS, Suh DC, Jang E, et al. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea. J Manag Care Pharm 2010 Jan; 16 (1): 32-45
32. Vespa G, Constenla DO, Pepe C, et al. Estimating the costeffectiveness of pneumococcal conjugate vaccination in Brazil. Rev Panam Salud Publica 2009 Dec; 26 (6): 518-28
33. De Wals P, Black S, Borrow R, et al. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clin Ther 2009 Oct; 31 (10): 2152-69
34. Wisloff T, Abrahamsen TG, Bergsaker MA, et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine 2006; 24 (29-30): 5690-9 (Pubitemid 43928192)
35. Riquelme PM, Gasquez Abad CI, Mena ME, et al. Acute otitis media in a pediatrics consulting office [in Spanish]. An Esp Pediatr 1996 May; 44 (5): 433-6 (Pubitemid 26200883)
36. Joki-Erkkila VP, Laippala P, Pukander J. Increase in paediatric acute otitis media diagnosed by primary care in two Finnish municipalities: 1994-5 versus 1978-9. Epidemiol Infect 1998 Dec; 121 (3): 529-34 (Pubitemid 29023030)
37. Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999 Dec; 38 (4-5): 339-44 (Pubitemid 30030067)
38. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989 Jul; 160 (1): 83-94 (Pubitemid 19162997)
39. Swiss Federal Office of Public Health; Swiss Sentinel Surveillance Network [online]. Available from URL: http:// www.bag.admin.ch/sentinella/ aktuell/e/index.htm [Accessed 2010 Apr 6]
40. Wang EE, Einarson TR, Kellner JD, et al. Antibiotic prescribing for Canadian preschool children: evidence of overprescribing for viral respiratory infections. Clin Infect Dis 1999 Jul; 29 (1): 155-60 (Pubitemid 29336818)
41. Hardy AM. Incidence and impact of selected infectious diseases in childhood. Vital Health Stat 10 1991 Oct; (180): 1-22
42. Claes C, Reinert R, Graf von der Schulenburg JM. Costeffectiveness of the conjugate vaccine PnC7 against pneumococcal infections in Germany. Discussion paper no. 25 of the Research Institute for Health Economics and Health Systems Research (in cooperation with the Medical High School Hanover). Version 1.2 [online]. Available from URL: http://www.ivbl.uni-hannover.de/~fgg/2005 [Accessed 2010 Apr 6]
43. General Practice Research Database (GPRD) [online]. Available from URL: http://www.gprd.com [Accessed 2010 Apr 6]
44. Garcés-Sá nchezM, Díez-Domingo J, Alvarez de Labiada T, et al. Epidemiology and burden of acute otitis media in Valencia (Spain) [in Spanish]. An Pediatr (Barc) 2004 Feb; 60 (2): 125-32 (Pubitemid 38418572)
45. Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006 Sep; 118 (3): 865-73 (Pubitemid 46090026)
46. National Board of Health and Welfare [online]. Available from URL: http://www.socialstyrelsen.se/en/ [Accessed 2010 Apr 6]
47. Health Insurance Review & Assessment Service Agency. National health insurance statistical yearbook. Seoul: HIRA, 2006
48. Petit G, De Wals P, Law B, et al. Epidemiological and economic burden of pneumococcal diseases in Canadian children. Can J Infect Dis 2003 Jul; 14 (4): 215-20 (Pubitemid 37295932)
49. Stangerup SE, Tos M. Epidemiology of acute suppurative otitis media. Am J Otolaryngol 1986 Jan; 7 (1): 47-54 (Pubitemid 16105379)
50. Dagan R. The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media. Curr Opin Otolaryngol Head Neck Surg 2004 Dec; 12 (6): 488-94 (Pubitemid 39565202)
51. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001 Dec; 10 (8): 751-74 (Pubitemid 34041387)
52. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010 May; 17 (5): 840-7
53. Brouwer CN, Maille AR, Rovers MM, et al. Health-related quality of life in children with otitis media. Int J Pediatr Otorhinolaryngol 2005 Aug; 69 (8): 1031-41 (Pubitemid 40956978)